{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:49:34Z","timestamp":1791902974287,"version":"4.3.4"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2002,8,12]],"date-time":"2002-08-12T00:00:00Z","timestamp":1029110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2002,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The optimal serum urate levels necessary for elimination of tissue deposits of monosodium urate in patients with chronic gout is controversial. This observational, prospective study evaluates the relationship between serum urate levels during therapy and the velocity of reduction of tophi in patients with chronic tophaceous gout.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Sixty\u2010three patients with crystal\u2010confirmed tophaceous gout were treated with allopurinol, benzbromarone, or combined therapy to achieve serum uric acid levels less than the threshold for saturation of urate in tissues. The tophi targeted for evaluation during followup were the largest in diameter found during physical examination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients taking benzbromarone alone or combined allopurinol and benzbromarone therapy achieved faster velocity of reduction of tophi than patients taking allopurinol alone. The velocity of tophi reduction was linearly related to the mean serum urate level during therapy. The lower the serum urate levels, the faster the velocity of tophi reduction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Serum urate levels should be lowered enough to promote dissolution of urate deposits in patients with tophaceous gout. Allopurinol and benzbromarone are equally effective when optimal serum urate levels are achieved during therapy. Combined therapy may be useful in patients who do not show enough reduction in serum urate levels with single\u2010drug therapy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.10511","type":"journal-article","created":{"date-parts":[[2002,10,6]],"date-time":"2002-10-06T12:12:48Z","timestamp":1033906368000},"page":"356-360","source":"Crossref","is-referenced-by-count":386,"title":["Effect of urate\u2010lowering therapy on the velocity of size reduction of tophi in chronic gout"],"prefix":"10.1002","volume":"47","author":[{"given":"Fernando","family":"Perez\u2010Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Calabozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose I.","family":"Pijoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Herrero\u2010Beites","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ruibal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,8,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(74)90634-2"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.57.4.255"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199805000-00014"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-90-5-812"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602153340707"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)89546-0"},{"key":"e_1_2_6_8_2","first-page":"142","article-title":"Treatment of gout","volume":"25","author":"Pawlotsky Y","year":"1996","journal-title":"Rheum Europe"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199909000-00020"},{"key":"e_1_2_6_10_2","first-page":"21","article-title":"Treatment of chronic gout: a new approach to an ancient disease","volume":"26","author":"Perez\u2010Ruiz F","year":"1999","journal-title":"Rev Esp Reumatol"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90743-5"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.231.11.1143"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.50.9.631"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780080502"},{"key":"e_1_2_6_15_2","first-page":"1621","article-title":"Should patients with interval gout be treated with urate lowering drugs?","volume":"22","author":"Fam AG","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_6_16_2","first-page":"618","article-title":"An evidence based appraisal of the management of nontophaceous interval gout","volume":"22","author":"Bosi\u2010Ferraz M","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(51)90028-9"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780090306"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780341203"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.42.Suppl_1.12"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780170207"},{"key":"e_1_2_6_22_2","first-page":"305","article-title":"Pharmacokinetic and clinical studies of a new uricosuric agent: benzbromarone","volume":"3","author":"Y\u00fc TF","year":"1975","journal-title":"J Rheumatol"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780190209"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/030006058100900615","article-title":"Benzbromarone therapy in hyperuricemia; comparison with allopurinol and probenecid","volume":"9","author":"Schepers GW","year":"1981","journal-title":"J Int Med Res"},{"key":"e_1_2_6_25_2","first-page":"383","article-title":"Benzbromarone as a long\u2010term uricosuric agent","volume":"122","author":"Bluestone R","year":"1980","journal-title":"Adv Exp Med Biol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1962.03620160005002"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.28.4.366"},{"key":"e_1_2_6_28_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/clinchem\/16.3.191","article-title":"Isolation and quantification of serum uric acid by absorption chromatography","volume":"16","author":"Simkin PA","year":"1970","journal-title":"Clin Chem"},{"key":"e_1_2_6_29_2","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1152\/ajplegacy.1971.221.4.1105","article-title":"Uric acid metabolism in Cebus monkey","volume":"221","author":"Simkin PA","year":"1971","journal-title":"Am J Physiol"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(79)90148-3"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00124743-199904000-00001"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.10511","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.10511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T03:53:07Z","timestamp":1696996387000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.10511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8,12]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,8,15]]}},"alternative-id":["10.1002\/art.10511"],"URL":"https:\/\/doi.org\/10.1002\/art.10511","archive":["Portico"],"relation":{},"ISSN":["0893-7524","1529-0123"],"issn-type":[{"value":"0893-7524","type":"print"},{"value":"1529-0123","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8,12]]}}}